{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:54Z","timestamp":1760146074941,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["1R01CA196941","1R01CA195651","U01CA196403","P01CA117969","P50CA221707"],"award-info":[{"award-number":["1R01CA196941","1R01CA195651","U01CA196403","P01CA117969","P50CA221707"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Adequate sampling is essential to an accurate pathologic evaluation of pancreatectomy specimens resected for pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT). However, limited data are available for the association between the sampling and survival in these patients. We examined the association of the entire submission of the tumor (ESOT) and the entire submission of the pancreas (ESOP) with disease-free survival (DFS) and overall survival (OS), as well as their correlations with clinicopathologic features, for 627 patients with PDAC who received NAT and pancreaticoduodenectomy. We demonstrated that both ESOT and ESOP were associated with lower ypT, less frequent perineural invasion, and better tumor response (p &lt; 0.05). ESOP was also associated with a smaller tumor size (p &lt; 0.001), more lymph nodes (p &lt; 0.001), a lower ypN stage (p &lt; 0.001), better differentiation (p = 0.02), and less frequent lymphovascular invasion (p = 0.009). However, since ESOP and ESOT were primarily conducted for cases with no grossly identifiable tumor or minimal residual carcinoma in initial sections, potential bias cannot be excluded. Both ESOT and ESOP were associated with less frequent recurrence\/metastasis and better DFS and OS (p &lt; 0.05) in the overall study population. ESOP was associated with better DFS and better OS in patients with ypT0\/ypT1 or ypN0 tumors and better OS in patients with complete or near-complete response (p &lt; 0.05). ESOT was associated with better OS in patients with ypT0\/ypT1 or ypN0 tumors (p &lt; 0.05). Both ESOT and ESOP were independent prognostic factors for OS according to multivariate survival analyses. Therefore, accurate pathologic evaluation using ESOP and ESOT is associated with the prognosis in PDAC patients with complete or near-complete pathologic response and ypT0\/ypT1 tumor after NAT.<\/jats:p>","DOI":"10.3390\/cancers16193312","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:19:33Z","timestamp":1727435973000},"page":"3312","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy"],"prefix":"10.3390","volume":"16","author":[{"given":"Mehran","family":"Taherian","sequence":"first","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H. G.","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-2361","authenticated-orcid":false,"given":"Laura R.","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-6381","authenticated-orcid":false,"given":"Dongguang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Tat","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongshan","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-1163","authenticated-orcid":false,"given":"Deyali","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-7288","authenticated-orcid":false,"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Ikoma","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-9058","authenticated-orcid":false,"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-3461","authenticated-orcid":false,"given":"Eugene J.","family":"Koay","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-9978","authenticated-orcid":false,"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-5863","authenticated-orcid":false,"given":"Huamin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jso.24630","article-title":"Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients","volume":"116","author":"Youngwirth","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological Benefits of Neoadjuvant Chemoradiation with Gemcitabine Versus Upfront Surgery in Patients with Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2\/3 Trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): A randomised, open-label, phase 2\u20133 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_7","unstructured":"Tempero, M.A., Malafa, M.P., Al-Hawary, M., Behrman, S.W., Berson III, A.B., Cardin, D.B., Cha, C., Chiorean, E.G., Chung, V., and Czito, B. (2021, January 25). NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma (Version 1.2021). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/pancreatic.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2016.67.5553","article-title":"Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Khorana","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000738","article-title":"Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma after Neoadjuvant Therapy as a Prognostic Indicator for Survival","volume":"40","author":"Lee","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.26243","article-title":"Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation","volume":"118","author":"Estrella","year":"2012","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PAS.0000000000002013","article-title":"Integrated Pathologic Score Effectively Stratifies Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy","volume":"47","author":"Sohn","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/PAS.0000000000001853","article-title":"Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations from the Pancreatobiliary Pathology Society","volume":"46","author":"Wang","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21037\/tgh.2019.06.02","article-title":"Pathology of pancreatic cancer","volume":"4","author":"Haeberle","year":"2019","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5858\/arpa.2019-0477-RA","article-title":"Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications","volume":"144","author":"Nagaria","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jso.27689","article-title":"The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy","volume":"130","author":"Carpenter","year":"2024","journal-title":"J. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s13304-023-01628-y","article-title":"Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: Does it affect prognosis?","volume":"75","author":"Donisi","year":"2023","journal-title":"Updates Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"zrad125","DOI":"10.1093\/bjsopen\/zrad125","article-title":"Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: Retrospective study","volume":"8","author":"Goess","year":"2024","journal-title":"BJS Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.hpb.2023.06.015","article-title":"Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemoradiotherapy-comparison of T category between the American Joint Committee on Cancer and Japan Pancreas Society","volume":"25","author":"Hayasaki","year":"2023","journal-title":"HPB"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1245\/s10434-024-15281-1","article-title":"Predictors for Long-Term Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis","volume":"31","author":"Javed","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/MPA.0000000000002326","article-title":"Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma","volume":"53","author":"Ahmad","year":"2024","journal-title":"Pancreas"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.pan.2021.08.011","article-title":"Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma","volume":"21","author":"Murata","year":"2021","journal-title":"Pancreatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/his.14086","article-title":"Pancreatic ductal adenocarcinoma: Tumour regression grading following neoadjuvant FOLFIRINOX and radiation","volume":"77","author":"Neyaz","year":"2020","journal-title":"Histopathology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.pan.2024.03.013","article-title":"Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study","volume":"24","author":"Park","year":"2024","journal-title":"Pancreatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1097\/JS9.0000000000000589","article-title":"Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: A retrospective cohort study","volume":"109","author":"Pu","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_25","first-page":"1097","article-title":"Lymph Node Yield is Associated with Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy","volume":"10","author":"Fong","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Usui, M., Uchida, K., Hayasaki, A., Kishiwada, M., Mizuno, S., and Watanabe, M. (2024). Prognostic impact of the distance from the anterior surface to tumor cells in pancreatoduodenectomy with neoadjuvant chemoradiotherapy for pancreatic ductal adenocarcinoma. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0307876"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5858\/arpa.2011-0144-RA","article-title":"Assessing treatment effect in pancreatic cancer","volume":"136","author":"Hartman","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pan.2018.04.010","article-title":"Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on","volume":"18","author":"Verbeke","year":"2018","journal-title":"Pancreatology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yokohira, M., Oshima, M., Yamakawa, K., Ye, J., Nakano-Narusawa, Y., Haba, R., Fukumura, Y., Hirabayashi, K., Yamaguchi, H., and Kojima, M. (2021). Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-86152-y"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11605-012-1853-2","article-title":"Number of lymph nodes evaluated: Prognostic value in pancreatic adenocarcinoma","volume":"16","author":"Huebner","year":"2012","journal-title":"J. Gastrointest. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/SLA.0000000000002668","article-title":"Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma","volume":"269","author":"Shi","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ejso.2013.07.089","article-title":"Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinoma","volume":"39","author":"Vuarnesson","year":"2013","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3312\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:05:27Z","timestamp":1760112327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":32,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16193312"],"URL":"https:\/\/doi.org\/10.3390\/cancers16193312","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}